South San Francisco, CA, United States of America

Francis Gosselin

This inventor holds 37 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 20 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Genentech, Inc., Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ag. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francis Gosselin. Retrieved from https://idiyas.com/inventor/francis-gosselin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 18)

% Patents Active = 94.6

CIPO Patents = 3 (Patent Applications = 14)

EPO Patents = 20 (Patent Applications = 27)

Average Co-Inventor Count = 7.0

ph-index = 5

Forward Citations = 92(Granted Patents)

Location History:

San Mateo, CA (US) (2014 - 2024)
South San Francisco, CA (US) (2016 - 2024)

Company Filing History:

Hoffmann-La Roche Inc.

patents

2 out of 181

F. Hoffmann-La Roche Ag

Sirna Therapeutics, Inc.

patents

9. 4 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

AKT Protein Kinase Inhibitors

NAMPT Inhibition

Quinazoline Compounds

Arylomycin Ring Analogs

BTK Inhibitors

Pyrimidinyl Compounds

Click Chemistry

Chemical Modification

Tricyclic Compounds

Sulfoxide Derivatives

Thienopyrimidine Compounds

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698284 - SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE (2026-08-04),

2. 12440492 - Pharmaceutical compositions comprising AKT protein kinase inhibitors (2025-10-14),

3. 12336981 - Compounds and compositions for the inhibition of NAMPT (2025-06-24),

4. 12172982 - Synthesis of quinazoline compounds (2024-12-24),

5. 12071422 - Process for synthesis of quinazoline compounds (2024-08-27),

6. 11999749 - Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto (2024-06-04),

7. 11969426 - Pharmaceutical compositions comprising Akt protein kinase inhibitors (2024-04-30),

8. 11780834 - Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use (2023-10-10),

9. 11702452 - Process for making arylomycin ring analogs (2023-07-18),

10. 11661424 - Process for preparing BTK inhibitors (2023-05-30),

11. 11547701 - Compounds and compositions for the inhibition of NAMPT (2023-01-10),

12. 11414412 - Process for the preparation of a medicament (2022-08-16),

13. 11337977 - Pharmaceutical compositions comprising Akt protein kinase inhibitors (2022-05-24),

14. 11325912 - Regio-selective synthesis of imidazo[1,2-a]pyrimidines (2022-05-10),

15. 11192924 - Process for making arylomycin ring analogs (2021-12-07),

Title: Inspiring Innovation: The Legacy of Francis Gosselin

Introduction:

Francis Gosselin, a visionary inventor based in South San Francisco, CA, has left an indelible mark on the world of technology with his relentless pursuit of excellence and passion for innovation. With an impressive portfolio of 31 patents to his name, Gosselin continues to inspire the next generation of inventors and shape the future of technology.

Latest Patents:

Among his latest patents is the groundbreaking invention of "Pharmaceutical compositions comprising Akt protein kinase inhibitors." These compositions demonstrate therapeutic activity against diseases such as cancer, showcasing Gosselin's commitment to advancing healthcare. Additionally, his invention of "Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol" represents a significant leap forward in the treatment of cancer.

Career Highlights:

Gosselin has made significant contributions to the field of biotechnology through his work at Genentech, Inc., where he played a pivotal role in developing cutting-edge pharmaceutical solutions. His sharp intellect and innovative approach have earned him recognition as a leader in the industry, with his patents paving the way for groundbreaking advancements in healthcare.

Collaborations:

Throughout his career, Gosselin has collaborated with esteemed professionals in the field, including Ngiap-Kie Lim and Haiming Zhang. Together, they have worked towards pushing the boundaries of innovation and creating solutions that have the potential to positively impact countless lives.

Conclusion:

Francis Gosselin's unwavering dedication to innovation and his remarkable insights have established him as a luminary in the world of technology. His legacy serves as a beacon of inspiration for aspiring inventors, reminding us all of the transformative power of ingenuity and perseverance in shaping a brighter future for all.

Profile summary based on public USPTO records.